• Tumor-Specific Genetic Engineering Enhances T Cell Immunity

  2026-06-03

  He et al. (2025) introduce a tumor-targeted plasmid, P αCD3&LIGHT, which synergistically drives T cell infiltration and activation in 'immune-cold' solid tumors. This strategy significantly augments the efficacy of immune checkpoint inhibitors and CAR-T therapies, with broad translational implications for solid tumor immunotherapy.

• Patient-Derived Gastric Cancer Assembloids Illuminate Tumor-

  2026-06-03

  This study introduces a patient-specific gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, recapitulating tumor heterogeneity and the microenvironment with high fidelity. The model enables exploration of drug response variability and resistance mechanisms, advancing personalized cancer research and preclinical assay design.

• Kaempferol Attenuates Melanocyte Ferroptosis in Vitiligo via

  2026-06-02

  This study elucidates how kaempferol protects human melanocytes from ferroptosis by modulating the NF-κB/PTGS2 signaling pathway—a mechanism highly relevant to vitiligo pathogenesis. The findings clarify the interplay between oxidative stress, inflammation, and iron-dependent cell death, offering new insights for translational ferroptosis research.

• FGF19-ELF4 Axis Drives Metastasis in Colorectal Cancer via F

  2026-06-02

  The referenced study uncovers how FGF19 promotes ELF4 overexpression, which in turn accelerates colorectal cancer metastasis by upregulating FGFR4 and SRC. These findings provide mechanistic insights into metastatic progression and highlight the potential of targeting the FGF19/ELF4/FGFR4/SRC axis for new therapeutic strategies.

• Demethyleneberberine as a Multi-Pathway Candidate in Hunting

  2026-06-01

  This article analyzes recent evidence proposing demethyleneberberine (DMB) as a potential neuroprotective agent for Huntington’s disease. The referenced study highlights DMB’s ability to modulate oxidative stress, mitochondrial dysfunction, and neuroinflammatory pathways implicated in HD, suggesting a multi-targeted therapeutic rationale.

• Optimizing Gene Delivery with 1,2-Dioleoyl-3-trimethylammoni

  2026-06-01

  1,2-Dioleoyl-3-trimethylammonium-propane chloride (DOTAP) enables efficient, scalable gene transfer and functional genomics screening by forming stable lipid–nucleic acid complexes. This article translates recent nanogranulate delivery breakthroughs into actionable protocols for maximizing DOTAP's performance in diverse experimental settings.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-05-31

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent optimized for amide bond formation in peptide synthesis, bioconjugation, and nucleotide coupling workflows. It is not recommended for in vivo or clinical applications due to a lack of supporting data and is best suited for controlled in vitro protocols requiring efficient coupling of carboxyl and amine groups.

• (R,S)-Anatabine: Amyloid Inhibition and Neuroinflammation Co

  2026-05-30

  (R,S)-Anatabine is a minor tobacco alkaloid that acts as an amyloid-beta inhibitor and NF-κB modulator. It enables dose-dependent reduction of soluble Aβ peptides in both cellular and animal models, supporting Alzheimer's disease research with verifiable, reproducible workflows.

• Targeting Glutamine Metabolism in HSCs to Alleviate Liver Fi

  2026-05-29

  The referenced study uncovers how modulating glutamine metabolism, particularly through SIRT4-mediated inhibition of glutamate dehydrogenase activity, can mitigate hepatic stellate cell-driven liver fibrosis. This mechanistic insight suggests new therapeutic avenues for chronic liver disease by targeting key metabolic enzymes in fibrosis progression.

• XXLP Targets NOX2/ROS/Mitochondria/NLRP3 Axis in Ulcerative

  2026-05-29

  This study reveals that Xu Chunfu’s Modified Xianglian Pill (XXLP) alleviates ulcerative colitis in mice by modulating the NOX2/ROS/mitochondria/NLRP3 axis and reshaping gut microbiota. The work advances mechanistic understanding of traditional therapies and identifies NOX2 as a molecular target for inflammation control.

• Elevating cDNA Synthesis: HyperScript™ RT for Translational

  2026-05-28

  This article delivers a mechanistic and strategic perspective on overcoming the persistent challenges of cDNA synthesis from complex RNA templates, with a focus on translational and clinical research contexts. It contextualizes HyperScript™ Reverse Transcriptase within the evolving landscape of molecular diagnostics, benchmarking its performance against both traditional and modern RT enzymes. Drawing from recent literature and practical use cases, the piece provides actionable protocol guidance and highlights workflow integration for quantitative PCR and beyond.

• Pentoxifylline: Strategic Insights for Translational Inflamm

  2026-05-28

  This article provides translational researchers with a mechanistic and strategic overview of Pentoxifylline—a non-specific phosphodiesterase inhibitor—highlighting its anti-inflammatory and immunomodulatory actions, optimal experimental use, and innovative delivery approaches. Drawing on recent advances such as niosomal co-formulations for psoriasis and validated in vitro protocols, it positions Pentoxifylline from APExBIO as a scientifically robust tool for advancing inflammation, immunology, and targeted therapy workflows.

• Palonosetron Hydrochloride: Precision 5-HT3 Receptor Antagon

  2026-05-27

  Palonosetron hydrochloride empowers cancer researchers with unmatched selectivity and prolonged 5-HT3 receptor inhibition, raising the standard for CINV/RINV models and transporter studies. This guide demystifies protocol design, advanced applications, and optimization strategies—translating reference study breakthroughs into actionable lab workflows.

• Maraviroc (UK-427857): Applied Workflows for CCR5 Antagonism

  2026-05-27

  Maraviroc (UK-427857) stands out as a gold-standard CCR5 antagonist, empowering research on HIV-1 entry inhibition, neuroinflammation, and rheumatoid arthritis. This article unpacks stepwise workflows, new disease models, and troubleshooting strategies, translating bench breakthroughs—like CCR5-targeted delivery in arthritis—into actionable protocols.

• Fluconazole: Optimizing Fungal Cytochrome P450 Inhibition in

  2026-05-26

  Fluconazole is the gold standard fungal cytochrome P450 enzyme 14α-demethylase inhibitor for dissecting antifungal resistance and biofilm dynamics in Candida albicans. This guide offers actionable workflows, troubleshooting tactics, and new insights from autophagy-focused resistance research, ensuring reproducibility and depth in antifungal experimentation.

16384 records 1/1093 page Next 12345 下5页 Last page